Ferraresso Michael 4
4 · AVEO PHARMACEUTICALS, INC. · Filed Jan 19, 2023
Insider Transaction Report
Form 4
Ferraresso Michael
Chief Commercial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−3,749→ 0 totalExercise: $30.80Exp: 2028-02-01→ Common Stock (3,749 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−100,000→ 0 totalExercise: $9.12Exp: 2031-02-05→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−42,499→ 0 totalExercise: $5.60Exp: 2030-02-05→ Common Stock (42,499 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−220,000→ 0 totalExercise: $3.67Exp: 2032-02-15→ Common Stock (220,000 underlying) - Disposition to Issuer
Common Stock
2023-01-19$15.00/sh−16,345$245,175→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−20,000→ 0 totalExercise: $28.30Exp: 2027-12-04→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-01-19−35,064→ 0 totalExercise: $6.20Exp: 2029-02-06→ Common Stock (35,064 underlying)
Footnotes (2)
- [F1]Pursuant to the Merger Agreement, at the Effective Time, each share of the Company's common stock automatically converted into the right to receive the Merger Consideration.
- [F2]This stock option was fully vested and exercisable prior to the Effective Time. Pursuant to the terms of the Merger Agreement, each option to purchase shares of the Company's common stock was canceled and converted into the right to receive an amount in cash, if any, equal to the product of (i) the excess, if any, of the Merger Consideration over the exercise price of such stock option and (ii) the number of shares of common stock underlying such option, less any applicable withholding taxes.